Skip to main content
. 2020 Dec 30:NEJMra2035343. doi: 10.1056/NEJMra2035343

Table 1. SARS-CoV-2 Vaccines under Emergency Use Authorization (EUA) or in Late-Phase Studies.

Vaccine Platform Type of Vaccine
and Immunogen		 Developer
(Name of Vaccine)		 Dose Schedule
and Administration		 Phase* Excipients†
RNA-based vaccine

  • mRNA encoding spike protein (30 μg)

 BioNTech–Pfizer
(BNT162b2)

  • Two doses (day 0, day 21)

  • Intramuscular

 Post-EUA 0.43 mg ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 0.05 mg
2[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide, 0.09 mg 1,2-distearoyl-sn-glycero-3-phosphocholine, and 0.2 mg cholesterol, 0.01 mg potassium chloride, 0.01 mg monobasic potassium phosphate, 0.36 mg sodium chloride, 0.07 mg dibasic sodium phosphate dihydrate, and 6 mg sucrose. The diluent (0.9% sodium chloride Injection) contributes an additional 2.16 mg sodium chloride per dose
RNA-based vaccine

  • mRNA encoding spike protein (100 μg)

 Moderna
(mRNA-1273)

  • Two doses (day 0, day 28)

  • Intramuscular

 Post-EUA Lipids (SM-102; 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 [PEG 2000-DMG]; cholesterol; and 1,2-distearoyl-sn-glycero-3-phosphocholine [DSPC]), tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate, and sucrose
Adenovirus vector
(nonreplicating)

  • ChAdOx1-Sn Cov-19

  • Nonreplicating chimpanzee AdV5 expressing spike protein

 AstraZeneca and University of Oxford
(AZD1222)

  • One (day 0) or two (day 0, day 28) doses

  • Intramuscular

 Phase 3 10 mM histidine, 7.5% (w/v) sucrose,
35 mM sodium chloride, 1 mM magnesium
chloride, 0.1% (w/v) polysorbate 80,
0.1 mM edetate disodium, 0.5% (w/v)
ethanol, at pH 6.6
Adenovirus vector
(nonreplicating)

  • Ad26.COV2.S

  • Adenovirus 26 vectored vaccine using AdVac and PER.C6 technology

 Janssen

  • One (day 0) or two (day 0, day 56) doses

  • Intramuscular

 Phase 3 Sodium chloride, citric acid monohydrate, polysorbate 80, 2 hydroxypropyl-B-cyclodextrin (HBCD), ethanol (absolute), sodium hydroxide
Protein subunit

  • Full-length recombinant SARS-CoV-2 glycoprotein nanoparticle with Matrix M adjuvant

  • Spike prefusion protein

 Novavax

  • Two doses (day 0, day 21)

  • Intramuscular

 Phase 3 Matrix M1 adjuvant
Full-length spike protein formulated in polysorbate 80 detergent and Matrix M1 adjuvant
Protein subunit

  • SARS-CoV-2 vaccine formulation with adjuvant (S-protein) (Baculovirus production)

  • Spike protein

 Sanofi Pasteur and GSK

  • Two doses (day 0, day 21)

  • Intramuscular

 Phase 1–2 Sodium phosphate monobasic monohydrate, sodium phosphate dibasic, sodium chloride polysorbate 20, disodium hydrogen phosphate, potassium dihydrogen phosphate, potassium chloride
*

Phase information was current as of December 21, 2020. In all cases, the placebo was normal saline.

†

Bold entries are excipients potentially related to vaccine reaction that may be cross-reactive to other excipients (e.g., PEG 2000 and polysorbate 80). SM-102, a component of the Moderna vaccine, is a proprietary ionizable lipid.